6505-00-564-7320 ( NDC00781-2997-05 , CIN-QUIN 300 , NDC00032-4020-05 )
NSN Information
| NSN | FSC | NIIN | Item Name | INC |
|---|---|---|---|---|
| 6505-00-564-7320 | 6505 | 005647320 | QUINIDINE SULFATE CAPSULES,USP | 3117 |
NSN Features
| MRC | Parameter | Characteristics |
|---|---|---|
| AKJA | ACTIVE MEDICAMENT MEDICINAL STRENGTH | 300.000 MILLIGRAMS QUINIDINE SULFATE ACTIVE INGREDIENT |
| THPE | THERAPEUTIC EQUIVALENT | ANY A RATED DRUG |
| CQLS | CAPSULE CONTENT FORM | POWDER |
| CQCT | PRIMARY CONTAINER TYPE | BOTTLE |
| CYLZ | CAPSULE PRIMARY CONTAINER CONTENT QUANTITY | 500.000 |
| AKJC | CAPSULE TYPE | HARD |
Manufacturing Part Numbers (SKUs)
| Part SKU | Cage | Status | RNVC | RNCC | SADC | DAC | RNAAC |
|---|---|---|---|---|---|---|---|
| NDC00781-2997-05 | 59043 | F | 2 | 3 | 6 | 54 | |
| CIN-QUIN 300 | 09779 | A | 1 | 5 | 6 | 54 | |
| NDC00032-4020-05 | 09779 | A | 2 | 3 | 6 | 54 |
Manufacturers
| Part SKU | Cage | Manufacturer | Type | Status |
|---|---|---|---|---|
| NDC00781-2997-05 | 59043 | GENEVA PHARMACEUTICALS INC | A | F |
| CIN-QUIN 300 | 09779 | SOLVAY PHARMACEUTICALS INC. | A | A |
| NDC00032-4020-05 | 09779 | SOLVAY PHARMACEUTICALS INC. | A | A |
FLIS Identification
| PMIC | ADPE Code | CRITL Code | DEMIL Code | DEMIL INTG | NIIN Asgt | ESD | HMIC | ENAC | Schedule-B | INC |
|---|---|---|---|---|---|---|---|---|---|---|
| U | X | A | 1 | 11/19/1 | P | 3004909120 | 3117 |
FLIS Management
| MOE | REC Rep Code | Mgmt Ctl | USC | Phrase Code | Phrase Statement |
|---|---|---|---|---|---|
| VA | V | K | U/I CONTAINS 500 EA |
Demilitarization Codes & Management
| DML | PMI | HMIC | ADP | CC | ESDC |
|---|---|---|---|---|---|
| A | U | P | X |
Miscellaneous Management
| MOE (S_A) | SOS | AAC | QUP | UI | SLC | CIIC | RC | MCC | SVC |
|---|---|---|---|---|---|---|---|---|---|
| VA | I | 0 | BT | M | U | V |
Management Control Army
| MATCAT 1 | MATCAT 2 | MATCAT 3 | MATCAT 4 5 | ARC |
|---|
Freight
| NMFC | NMFC SUB | UFC | HMC | LTL | LCL | WCC | TCC | SHC | ADC | ACC | ASH | NMF DESC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|